Clinical impact of false-negative sentinel node biopsy in primary breast cancer

The British journal of surgery

Volumn 89, Issue 11, 2002, Pages 1430-1434

  Nano, M T ^a   Kollias, J ^a,b   Farshid, G ^c   Gill, P G ^a,b   Bochner, M ^a,b  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BREAST TUMOR; FEMALE; HUMAN; LABORATORY DIAGNOSIS; LUNG CARCINOMA; LYMPH NODE METASTASIS; METASTASIS; METHODOLOGY; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY; STANDARD;

AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FALSE NEGATIVE REACTIONS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SENTINEL LYMPH NODE BIOPSY;

EID: 0036833449     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.2002.02233.x     Document Type: Article

References (29)

1. 1 Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bendoni M et al. Sentinel‐node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph‐nodes. Lancet 1997 ; 349: 1864–7.
2. 2 Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994 ; 220: 391–8.
3. 3 Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997 ; 15: 2345–50.
4. 4 Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C et al. The sentinel node in breast cancer–a multicenter validation study. N Engl J Med 1998 ; 339: 941–6.
5. 5 Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg 1998 ; 227: 645–53.
6. 6 Hill ADK, Tran KN, Akhurst T, Yeung H, Yeh SDJ, Rosen PP et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999 ; 229: 528–35.
7. 7 Nieweg OE, Rutgers EJT, Jansen L, Valdes Olmos RA, Peterse JL, Hoefnagel KA et al. Is lymphatic mapping in breast cancer adequate and safe? World J Surg 2001 ; 25: 780–8.
8. 8 Kollias J, Gill PG, Chatterton BE, Hall VE, Bochner MA, Coventry BJ et al. Reliability of sentinel node status in predicting axillary lymph node involvement in breast cancer. Med J Aust 1999 ; 171: 461–5.
9. 9 Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24 740 breast cancer cases. Cancer 1989 ; 63: 181–7.
10. 10 Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast center: results of a national survey by the American College of Surgeons. Cancer 1980 ; 45: 2917–24.
11. 11 Forrest AP, Everington D, McDonald CC, Steele RJ, Chetty U, Stewart HJ. The Edinburgh randomized trial of axillary sample or clearance after mastectomy. Br J Surg 1995 ; 82: 1504–8.
12. 12 Fisher B, Redmond C, Fisher ER, Bauer M, Wolmark N, Wickerham DL et al. Ten‐year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985 ; 312: 674–81.
13. 13 Cady B, Stone MD, Schuler JG, Thakur R, Wanner MA, Lavin PT. The new era in breast cancer. Invasion, size, and lymph nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996 ; 131: 301–8.
14. 14 Jamali FR, Kurtzman SH, Deckers PJ. Role of axillary dissection in mammographically detected breast cancer. Surg Oncol Clin N Am 1997 ; 6: 343–58.
15. 15 Haffty BG, Ward B, Pathare P, Salem R, McKhann C, Beinfield M et al. Reappraisal of the role of axillary lymph node dissection in the conservative treatment of breast cancer. J Clin Oncol 1997 ; 15: 691–700.
16. 16 Kollias J, Gill PG, Coventry BJ, Malycha P, Chatterton BE, Farshid G. Clinical and histological factors associated with sentinel node identification in breast cancer. Aust N Z J Surg 2000 ; 70: 485–9.
17. 17 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long‐term follow‐up. Histopathology 1991 ; 19: 403–10.
18. 18 Pinder SE, Ellis IO, Galea M, O'Rourke S, Blamey RW, Elston CW. Pathological prognostic factors in breast cancer. III. Vascular invasion: relationship with recurrence and survival in a large study with long‐term follow‐up. Histopathology 1994 ; 24: 41–7.
19. 19 Todd JH, Dowle C, Williams MR, Elston CW, Ellis IO, Hinton CP et al. Confirmation of a prognostic index in primary breast cancer. Br J Cancer 1987 ; 56: 489–92.
20. 20 Galea MH, Blamey RW, Elston CE, Ellis IO. The Nottingham Prognostic Index in primary breast cancer. Breast Cancer Res Treat 1992 ; 22: 207–19.
21. 21 Farshid G, Pradhan M, Kollias J, Gill PG. Computer simulations of lymph node metastasis for optimizing the pathologic examination of sentinel lymph nodes in patients with breast carcinoma. Cancer 2000 ; 89: 2527–37.
22. 22 Cody HS III, Borgen OI. State‐of‐the‐art approaches to sentinel node biopsy for breast cancer: study design, patient selection, technique, and quality control at Memorial Sloan‐Kettering Cancer Center. Surg Oncol 1999 ; 8: 85–91.
23. 23 Moffat FL Jr, Senofsky GM, Davis K, Clark KC, Robinson DS, Ketcham AS. Axillary node dissection for early breast cancer: some is good, but all is better. J Surg Oncol 1992 ; 51: 8–13.
24. 24 Rampaul RS, Miremadi A, Pinder SE, Lee A, Ellis IO. Pathological validation and significance of micrometastasis in sentinel nodes in primary breast cancer. Breast Cancer Res 2001 ; 3: 113–16.
25. 25 Mann BG, Buchanan M, Collins PJ, Lichtenstein M. High incidence of micrometastases in breast cancer sentinel nodes. Aust N Z J Surg 2000 ; 70: 786–90.
26. 26 Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg 1995 ; 222: 394–401.
27. 27 Fisher ER, Anderson S, Redmond C, Fisher B. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B‐06: 10‐year pathologic and clinical prognostic discriminants. Cancer 1993 ; 71: 2507–14.
28. 28 Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000 ; 88: 608–14.
29. 29 Burak WE, Hollenbeck ST, Zervos EE, Hock KL, Kemp LC, Young DC. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002 ; 183: 23–7.